The Priority Review

Tag

bipolar mania

1 story

Stories

  1. Regulation

    Johnson & Johnson seeks FDA approval for CAPLYTA in bipolar mania

    Johnson & Johnson (NYSE: JNJ) filed a supplemental New Drug Application with the FDA to seek approval of CAPLYTA (lumateperone) for the treatment of manic or mixed episodes associated with bipolar I disorder in adults. The submission is supported by two pivotal Phase 3 studies that showed CAPLYTA significantly reduced manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3.